ORCID "0000-0003-2538-8569" Makale Koleksiyonu için listeleme
-
Effect of taxifolin on doxorubicin-induced oxidative cardiac damage in rats: A biochemical and histopathological evaluation
Aldemir, Mehmet Naci; Kara, Ali Veysel; Mammadov, Renad; Yazıcı, Gülce Naz; Çiçek, Betül; Yavuzer, B.; Coşkun, Reşit; Sakin, Abdullah; Gülaboğlu, Mine; Süleyman, Halis (Pakistan Agricultural Scientists Forum, 2024)Doxorubicin is a widely used anthracycline-derived broad-spectrum antitumoral antibiotic drug. However, cardiotoxicity due to doxorubicin treatment has warranted dose reduction or complete discontinuation in certain cases. ... -
Efficacy of capecitabine and temozolomide regimen in neuroendocrine tumors: Data from the Turkish oncology group
Ünal, Çağlar; Azizy, Abdulmunir; Karabulut, Senem; Taştekin, Didem; Akyıldız, Arif; Yaşar, Serkan; Yalçın, Şuayib; Çoban, Eyüp; Evrensel, Türkkan; Kalkan, Ziya; Sağlam, Sezer (Oxford University Press, 2023)Introduction: This study aims to report the efficacy and safety of capecitabine plus temozolomide (CAPTEM) across different lines of treatment in patients with metastatic neuroendocrine tumors (NETs).Methods: We conducted ... -
Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
Karacin, Cengiz; Öksüzoğlu, Berna; Demirci, Ayşe; Keskinkılıç, Merve; Baytemür, Naziyet Köse; Yılmaz, Funda; Selvi, Oğuzhan; Erdem, Dilek; Avşar, Esin; Paksoy, Nail; Demir, Necla; Göksu, Sema Sezgin; Türker, Sema; Bayram, Ertuğrul; Çelebi, Abdüssamet; Yılmaz, Hatice; Kuzu, Ömer Faruk; Kahraman, Seda; Gökmen, İvo; Sakin, Abdullah (BioMed Central Ltd, 2023)Background: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which ... -
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy
Kılıçkap, Saadettin; Öztürk, Akın; Karadurmuş, Nuri; Korkmaz, Taner; Yumuk, Perran Fulden; Çiçin, İrfan; Paydaş, Semra; Çılbır, Ebru; Şakalar, Teoman; Uysal, Mükremin; Yeşil Çınkır, Havva; Üskent, Necdet; Demir, Necla; Sakin, Abdullah; Dursun, Oldaç Uras; Aver, Birkan; Turhal, Nazım Serdar; Keskin, Serkan; Tural, Deniz; Eralp, Yeşim; Buğdaycı Başal, Fatma; Yaşar, Hatime Arzu; Şendur, Mehmet Ali Nahit; Demirci, Umut; Çubukçu, Erdem; Karaağaç, Mustafa; Çakar, Burcu; Tatlı, Ali Murat; Yetişyiğit, Tarkan; Urvay, Semiha; Gürsoy, Pınar; Oyan, Başak; Turna, Zeynep Hande; Işıkdoğan, Abdurrahman; Ölmez, Ömer Fatih; Yazıcı, Ozan; Çabuk, Devrim; Şeker, Mehmet Metin; Ünal, Olçun Ümit; Meydan, Nezih; Okutur, Sadi Kerem; Tunalı, Didem; Erman, Mustafa (2024)To evaluate radiological and clinical features in metastatic anaplastic lymphoma kinase+ non-small cell lung cancer patients and crizotinib efficacy in different lines. This national, non-interventional, multicenter, ... -
The prognostic effect of pretreatment 18F-FDG PET/CT metabolic parameters in locally advanced esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
Sakin, Abdullah; Özçelik, Mahsun; Şahin, Süleyman; Aydemir, Ozan; Aldemir, Mehmet Naci; İliklerden, Ümit Haluk; Kotan, Mehmet Çetin (Elsevier Science Ltd, 2022)Introduction: In this study, we aimed to examine the relation between pre-treatment 18F-FDG PET/CT metabolic parameters [(including the maximum standard uptake value (SUVmax), metabolic tumor volume (MTV), and tumor lesion ...